FILTER
FILTERED INTERVIEW RESULTS
Sam Taylor
PRESIDENT, THE NORTH CAROLINA BIOSCIENCES ORGANIZATION (NCBIO)
NCBIO is dedicated to promoting the future growth and development of North Carolina’s bioscience industry.
Hugh Davis
CHIEF BUSINESS OFFICER, FRONTAGE LABORATORIES
Frontage Laboratories operates as a contract research organization that provides scientific and analytical services to pharmaceutical and biotech companies.
Olivier Safir
CEO, PACT AND PARTNERS, LLC
Pact and Partners is an executive search firm dedicated to the life sciences industry since 1987.
Christopher Molineaux
PRESIDENT & CEO, LIFE SCIENCES PENNSYLVANIA
Founded in 1989, Life Sciences Pennsylvania (LSPA) is a statewide trade association for Pennsylvania’s life sciences industry.
Nicole Bishop
CEO AND FOUNDER, QUARTOLIO
Quartolio is an AI-powered knowledge management platform that accelerates research by connecting the dots across scholarly data, documents and discussions.
Mike Guerra
PRESIDENT & CEO, CALIFORNIA LIFE SCIENCES ASSOCIATION (CLSA)
California Life Sciences Association (CLSA) is the trade association representing California’s life sciences sector.
Jim Neal
CEO, XOMA
XOMA is a royalty monetizer acquiring early clinical-stage milestone and royalty assets.
Alan Rubino
CEO, EMISPHERE TECHNOLOGIES
Emisphere Technologies is a leading company in converting injectable therapeutics into advanced oral formulations.
Stephen Wang & Ryan Yoder
CHAIRMAN and CEO & VP BUSINESS DEVELOPMENT, KINGCHEM LIFE SCIENCE
Kingchem provides contract development and manufacturing services to the pharmaceutical and chemical industries.
Karen Fallen
SENIOR VICE PRESIDENT: BUSINESS UNIT HEAD - CLINICAL DEVELOPMENT & MANUFACTURING, LONZA
Lonza is one of the world's leading suppliers to the pharma, biotech and specialty ingredient markets.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
